CLINICAL_TRIALS
trial_result
· 2014-11-26
Clinical Trial Update: Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]
Summary
Phase 2 trial investigating bevacizumab for recurrent or persistent endometrial cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-11-26